Group 1: Market Movements - Several biotech and healthcare companies experienced notable gains in after-hours trading, driven by earnings updates, guidance announcements, and broader investor sentiment [1] - FibroBiologics, Inc. (FBLG) led with a 7.68% increase, closing at $0.41, suggesting speculative interest or technical momentum [1] - Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary results for Q4 and full year 2025, along with revenue guidance for Q1 2026 [2] - Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49, continuing a trend of volatility despite no new news [2] - Revvity, Inc. (RVTY) gained 4.92% to close at $109.00, with investors likely reacting to a previous collaboration announcement with Eli Lilly [3] - Option Care Health, Inc. (OPCH) rose 3.28% to $33.11 after releasing preliminary unaudited financial results for Q4 and full year 2025, along with guidance for 2026 [4] - Actinium Pharmaceuticals, Inc. (ATNM) added 3.02% to close at $1.34, reflecting investor activity in the broader biotech sector [4] - Design Therapeutics, Inc. (DSGN) gained 1.97% to $9.30, indicating continued interest despite no specific news [5] Group 2: Company-Specific Developments - FibroBiologics, Inc. (FBLG) showed a significant rise without any company-specific news, indicating potential speculative interest [1] - Nyxoah SA (NYXH) provided revenue guidance for Q1 2026, which bolstered investor confidence in its growth trajectory [2] - Revvity, Inc. (RVTY) is expanding access to predictive models through a collaboration with Eli Lilly, aimed at accelerating AI-enabled drug discovery [3] - Option Care Health, Inc. (OPCH) released preliminary financial results and guidance, contributing to its positive after-hours reaction [4]

Group 1 - Alpha Cognition Inc. (ACOG) is a stock in the Medical sector, which includes 950 individual stocks and has a Zacks Sector Rank of 4 [2] - ACOG currently holds a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past three months, the Zacks Consensus Estimate for ACOG's full-year earnings has increased by 30%, reflecting improved analyst sentiment [4] Group 2 - Year-to-date, ACOG has returned approximately 8.2%, outperforming the average gain of 6.5% for Medical stocks [4] - ACOG belongs to the Medical - Biomedical and Genetics industry, which consists of 467 stocks and is currently ranked 91 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have gained an average of 19.9% this year, indicating that ACOG is slightly underperforming its industry [6] Group 3 - Actinium Pharmaceuticals (ATNM) is another Medical stock that has outperformed the sector with a year-to-date increase of 15.1% [5] - The consensus estimate for Actinium Pharmaceuticals' current year EPS has risen by 11.7% over the past three months, and it also holds a Zacks Rank of 2 (Buy) [5] - The Medical - Drugs industry, to which Actinium Pharmaceuticals belongs, has moved up by 7.9% this year and is currently ranked 79 [7]

Group 1 - Alpha Cognition Inc. (ACOG) is a stock that has gained attention for its performance compared to the Medical sector, with a year-to-date gain of 5.8% against the sector average of 4.9% [4] - ACOG is part of the Medical sector, which consists of 950 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The Zacks Rank for ACOG is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Group 2 - Over the past 90 days, the Zacks Consensus Estimate for ACOG's full-year earnings has increased by 30.7%, reflecting improved analyst sentiment [4] - ACOG is categorized under the Medical - Biomedical and Genetics industry, which includes 468 companies and has an average gain of 16.5% this year, indicating ACOG is slightly underperforming its industry [6] - Another stock in the Medical sector, Actinium Pharmaceuticals (ATNM), has outperformed with a year-to-date return of 13.5% and a Zacks Rank of 2 (Buy) [5][6]

Group 1 - Armata Pharmaceuticals, Inc. (ARMP) has shown strong performance in the Medical sector, returning about 60% year-to-date, significantly outperforming the sector average of -2.3% [4] - The Zacks Rank for Armata Pharmaceuticals is 2 (Buy), indicating positive analyst sentiment and a stronger earnings outlook, with a 24.7% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Armata Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, which has an average gain of 3.3% this year, positioning ARMP as a better performer within this specific industry [5] Group 2 - The Medical sector includes 973 individual stocks and currently holds a Zacks Sector Rank of 6, reflecting the average strength of the sector [2] - Another stock in the Medical sector, Actinium Pharmaceuticals (ATNM), has also outperformed the sector with a year-to-date return of 27.8% and a Zacks Rank of 2 (Buy) [4][5] - The Medical - Drugs industry, where Actinium Pharmaceuticals is categorized, has 155 stocks and has moved up by 10.1% since the beginning of the year, indicating a relatively strong performance compared to the broader Medical sector [6]

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/actinium-law ...

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/actinium-law ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's drug approval process [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from October 31, 2022, to August 2, 2024 [2]. - Allegations include that the company made materially false statements and failed to disclose critical information regarding the Phase 3 Sierra trial data and its implications for FDA approval of the Iomab-B BLA [2]. Allegations Against the Company - The complaint states that the data from the Phase 3 Sierra trial was unlikely to meet FDA guidelines for approval [2]. - Additional analyses provided to the FDA to support the Iomab-B BLA were also unlikely to satisfy the FDA's requirements [2]. - As a result, the FDA was expected to refuse to review the Iomab-B BLA or deny approval if it did consider the application [2]. - The company's positive statements about its business and prospects were deemed materially misleading [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 27, 2025, to participate in the case [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software [3]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Solaris Energy Infrastructure, Actinium Pharmaceuticals, Bakkt Holdings, and Cerevel Therapeutics, with specific allegations of misleading statements and omissions of material facts regarding their business operations and prospects [1]. Solaris Energy Infrastructure, Inc. (NYSE: SEI) - Class period is from July 9, 2024, to March 17, 2025, with a lead plaintiff deadline of May 27, 2025 [2]. - Allegations include failure to disclose that Mobile Energy Rentals LLC had minimal corporate history, lacked a diversified earnings stream, and was co-owned by a convicted felon associated with turbine-related fraud [2]. - Claims that Solaris overstated commercial prospects from an acquisition and inflated profitability metrics by not properly depreciating turbines, leading to materially misleading statements [2]. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - Class period is from October 31, 2022, to August 2, 2024, with a lead plaintiff deadline of May 26, 2025 [3]. - The complaint alleges that Actinium made false claims regarding the strength of data submitted to the FDA for its Biologics License Application for Iomab-B, later admitting the need for additional clinical trials [3]. - Public statements were deemed materially misleading, resulting in investor damages when the truth was revealed [3]. Bakkt Holdings, Inc. (NYSE: BKKT) - Class period is from March 25, 2024, to March 17, 2025, with a lead plaintiff deadline of June 2, 2025 [4]. - Allegations include misrepresentation of the stability and diversity of crypto services revenue, which was heavily reliant on a single contract with Webull [4]. - Positive statements about the company's business were claimed to be materially misleading due to undisclosed dependencies [4]. Cerevel Therapeutics Holdings, Inc. (CERE) - Class period is from October 11, 2023, to August 1, 2024, with a lead plaintiff deadline of June 3, 2025 [6]. - The complaint alleges that Cerevel's offering documents omitted material facts about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [6]. - Claims that Cerevel's controlling shareholder acquired shares at an artificially depressed price while possessing nonpublic information, leading to a substantial windfall when AbbVie announced the acquisition at $45 per share [6][7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025 [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that during the Class Period, defendants made false or misleading statements regarding Actinium's data and its likelihood of FDA approval for the Iomab-B Biologics License Application [5] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] Group 3: Case Specifics - The lawsuit alleges that Actinium's data from the Sierra Trial was unlikely to meet FDA guidelines, which could lead to the rejection of the Iomab-B BLA [5] - The claims include that the additional analyses provided to the FDA were also unlikely to satisfy the necessary guidelines, leading to materially misleading statements about Actinium's business prospects [5]

LOS ANGELES, April 15, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Actinium Pharmaceuticals, Inc. ("Actinium " or the "Company") (NYSE: ATNM) investors of a class action representing investors that bought securities between October 31, 2022 to August 2, 2024, inclusive (the "Class Period"). Capri investors have until May 27, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their l ...